Repare Therapeutics Announces Preliminary RP-1664 Phase 1 Trial Data

Repare Therapeutics Inc. (NASDAQ:RPTX) announced on October 22, 2025, that the abstract related to its Phase 1 LIONS trial of RP-1664 has been made available.

The preliminary data contained within the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. The abstract, titled 'Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification', pertains to RP-1664, a first-in-class PLK4 inhibitor being evaluated as a monotherapy for advanced solid tumors.